31 results about "Neurogenesis" patented technology

Disclosed are in vitro methods for the differentiation of precursor cells into a neural crest cell (NCC) primed to a neurogenic lineage. The methods may include, for example, the steps of activating a Hedgehog signaling pathway (“HH signaling pathway”) in a precursor cell, wherein the precursor cell may be contacted with a neural crest cell induction medium for differentiation of the precursor cell into a neural crest cell. Compositions for carrying out the disclosed methods are also disclosed.

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and / or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and / or treating a disease, disorder, and / or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

Disclosed in the present invention is a phosphatidylserine and docosahexaenoic acid (DHA) composite, and its application thereof in a functional preparation, belonging to the field of health-care food. By combining two substances in a specific ratio and further applying them to edible functional preparations, brain entry efficiency of unsaturated fatty acids including DHA is improved. The ratio verifies a synergistic interaction mechanism of two active ingredients. Phosphatidylserine promotes enrichment of fatty acids such as the DHA in a brain by enhancing permeability of a blood-brain barrier, promotes neurogenesis, and enhances learning and memory abilities. Moreover, combination of the phosphatidylserine (PS) and the DHA can significantly improve an expression level of neurotrophic factors and protect and repaire a nervous system. (Figl)

The invention provides a traditional Chinese medicine compound composition with a nerve repairing effect, a cell culture medium, a traditional Chinese medicine-neural stem cell exosome compound and application, and belongs to the technical field of biological medicine. Based on the basic theory of traditional Chinese medicine and the combined theory of traditional Chinese medicine and western medicine, the traditional Chinese medicine compound composition is provided and comprises gastrodia elata exosomes, astragalus membranaceus exosomes and resveratrol, the traditional Chinese medicine compound composition is prepared into a cell culture medium, neural stem cells are cultured through the cell culture medium, and the neural stem cells are obtained. Therefore, the traditional Chinese medicine-neural stem cell exosome compound with an efficient nerve repairing function is prepared. The traditional Chinese medicine-neural stem cell exosome compound achieves the purpose of comprehensively repairing nerve injury by precisely targeting nerve cells, promoting neurogenesis, repairing the function of a neural circuit and reducing the inflammatory effect, and can be used for preparing related medical instruments and drugs for nerve repair.

Methods and composition are provided for treatment of various disorders associated with decreased neurogenesis, including age-related neurodegeneration, such as Alzheimer' s disease.

Provided is a technology capable of promoting neurogenesis. This neurogenesis promoter contains at least one of a substance that inhibits the glutaminolysis pathway and a substance that inhibits mTOR, and is used between postnatal day 0 and corrected age of 20 months of a premature infant.

This invention provides a pH-responsive immunomodulatory microneedle patch, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention incorporates Zif-8 nanoparticles loaded with ChABC into GelMA hydrogel to prepare a pH-responsive immunomodulatory microneedle patch (Z@C-MN). As the patch gradually degrades, the system can continuously release Zn in a pH-responsive manner. 2+ Z@C-MN, along with ChABC, promotes in situ repair of cerebral fibrosis (SCI) after injury. Z@C-MN induces macrophage polarization towards a pro-regenerative phenotype, thereby downregulating the inflammatory response, increasing neurite length, and promoting the differentiation of neural stem cells into neurons. In vivo, Z@C-MN reduced the inflammatory microenvironment after injury and promoted angiogenesis in a rat SCI model. Furthermore, it activated axonal regeneration by inhibiting scar tissue formation and regulating CD4+. + T cell transformation supports neurogenesis.

The present application relates to a composition using an endothelin B receptor agonist, such as Sovastatin (N-succinyl-[Glu9, Ala11, 15] endothelin 1, IRL-1620), for promoting cell proliferation and protecting the original neuroepithelium of cochlear and vestibular cells located within the ear sac. The pharmaceutical composition is systemically administered by means of tympanic membrane puncture, cochleostomy or intravenous or intramuscular injection. A pharmaceutical composition for the treatment of sensorineural hearing loss and vestibular disorders caused by inner ear cell degeneration, the pharmaceutical composition comprising a compound of an endothelin analogue, the use being treated by the neuroprotection and neurogenesis mechanism of cochlear vestibular hair cells and synapses.

The invention discloses a pharmaceutical composition for promoting neuron neogenesis and a method for promoting neuron neogenesis by using a gastrodia elata extract or an adenosine analogue. The gastrodia elata extract comprises gastrodin, gastrodigenin, a parishins compound, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde (4-hydroxybenzaldehyde). The invention also discloses a method for promoting neuron neogenesis by using the gastrodia elata extract or the adenosine analogue. The gastrodia elata extract provided by the invention has aging-retarding activity on nerve cells and can induce mouse hippocampal neuronal neogenesis.

A method and structure are disclosed. An example neural network is provided comprising multiple neurons including a subset of neurons comprising a majority of the multiple neurons, wherein each neuron of the subset of neurons has upstream neurons and downstream neurons interconnected through connections in a manner such that the connections for each neuron to other neurons are unconstrained within defined limits so that the neural network has an amorphous shape that is not predefined within the constrained limits. A neurogenesis method for creating the example network is disclosed.

The application belongs to the technical field of biotechnology, and specifically discloses application of Olig2 in transdifferentiation of astrocytes into functional neurons, and provides overexpression of a neurogenesis-promoting transcription factor and knockdown of an inducible hindering factor, which are expected to be effective methods for improving transdifferentiation efficiency and generating more newborn neurons, and thus are widely applied to treatment of various nervous system diseases related to neuron loss, such as neurodegenerative diseases and traumatic diseases of the central nervous system.

This invention provides a neurodevelopmental drug screening system and its applications based on a set of microglia markers. Specifically, this invention provides a neurodevelopmental supportive microglia subset that expresses markers of neurogenesis and development, as well as energy metabolism. This invention also provides a neurodevelopmental drug screening system and method using changes in the state of this cell subset as the core evaluation indicator. The system of this invention can sensitively and quantitatively reflect the regulatory effect of candidate drugs on the pro-neural maturation function of microglia in developmental brain injury, filling the technical gap in existing drug screening systems that lack "developmental immune-metabolic-synaptic linkage indicators."

The invention discloses a chemical reprogramming multifunctional mesenchymal stromal cell based on a glycyrrhizic acid solubilizing technology and application thereof. According to the invention, a specific chemical small molecule combination is adopted, and human fibroblasts are reprogrammed into multifunctional mesenchymal stromal cells (CiMFSCs) with high expression of NSMF / NAV2 / BMP4 / LAMA2 and other genes. The key advantage of the CiMFSCs is that the CiMFSCs can target a plurality of key links of cerebral arterial thrombosis treatment at the same time, including promotion of neurogenesis, angiogenesis, repair of blood brain barrier (BBB) and exertion of paracrine function, so that effective neural function recovery is finally realized. Compared with umbilical cord mesenchymal stem cells, neural stem cells differentiated by iPSC, vascular endothelial cells differentiated by iPSC and pericytes differentiated by iPSC, the CiMFSCs show a remarkable and superior treatment effect in a stroke model mouse: the CiMFSCs can remarkably reduce the cerebral infarction volume, improve the survival rate of the model mouse, improve the neurobehavioral score and realize comprehensive repair of nerve and blood vessel units.

Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.

The invention discloses an application of HOPX in improving / treating hippocampal dependent dysmnesia. According to the present invention, the rejuvenation or the function up-regulation of the HOPX is directly associated with the aging reversal-related hippocampus memory decline for the first time, and the brand new path and the strategy for treating the age-related cognitive impairment are opened up; in-vivo experiments prove that retrophication / overexpression of HOPX can directly resist hippocampal neurogenesis reduction caused by aging and improve phenotypes from cell and molecule levels. The invention provides a solid theoretical and experimental basis for developing HOPX-based gene therapy, protein drugs or small molecule agonists, and has a good transformation application prospect.

The present application provides a combination product for the treatment and / or prevention of psychiatric and / or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and / or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and / or removes the hallucinogenic and / or psychedelic side effects caused by the first compound.

In some aspects, disclosed herein are methods and compositions for treatment or prevention of cerebral palsy using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neurogenesis and / or reducing inflammation in a subject. In some cases, the disclosed methods comprise use of conditioned fibroblasts. Fibroblasts may be conditioned with agents capable of enhancing therapeutic efficacy, for example oxytocin and / or human chorionic gonadotrophin (hCG).

The invention relates to a neural stem cell-parathymosin composite cell preparation and application thereof in treatment of nerve injury diseases. According to the invention, it is found for the first time that neural stem cells overexpressing parathymosin (PTMS) can effectively promote neuron neogenesis and axon growth in in-vitro and in-vivo experiments; animal experiment results show that the traditional Chinese medicine composition can also be used as a treatment means for promoting nerve regeneration to resist dyskinesia related to nerve injury diseases.

The invention provides application of tauroursodeoxycholate in prevention or treatment of mitochondrial encephalopathy, and belongs to the technical field of medicine. The core of the invention lies in that the pathological mechanism of the mitochondrial encephalopathy is coped with by utilizing multiple biological effects of the TUDCA. In-vivo and in-vitro experiments find that after a cKO mouse is treated by TUDCA, the expression of an endoplasmic reticulum stress marker Atf4 and fatty acid synthase (Fasn) in the mouse can be remarkably reduced, and abnormal accumulation of lipid is reduced, so that the metabolic state of cells is improved. In animal models, treatment with TUDCA not only alleviates dyskinesia, but also promotes the neurogenesis process and extends the survival time of mice.

The present invention provides methods for reducing amyloid beta formation and for treating diseases associated with the accumulation of amyloid beta. The present invention provides (1) A β aggregation inhibition by A β Oligomer / Fibril formation inhibition, (2) BACE-1 reduction through β-Amyloidogenic Processing inhibition, (3) increased cerebral blood flow, (4) activation of Neuronal cell Death inhibition and Neurogenesis, Synaptogenesis, Angiogenesis promotion, (5) DKK-1 inhibition by Wnt Signaling and Aβ production Positive Feedback Loop for inhibition of APP to suppress Aβ accumulation, (6) Autophagy activation by cells, by providing Mirodenafil, Sildenafil, Vardenafil, Tadalafil, Udenafil, Dasantafil, and Avanafil and a Pharmaceutically Acceptable Salt, Solvate, and Hydrate in selected compounds key of ingredient containing drug compound composition, and this with the treatment method provided.

Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.

The invention discloses application of a bone cell specific Wnt signal in critical bone defect repair, and relates to the field of medicine. A 3D printed composite scaffold for use in the treatment of critical bone defects, bone nonunion or osteoporosis, which is applied in the form of a 3D printed composite scaffold comprising bio-ink and polycaprolactone PCL, the bio-ink comprising a bone-derived acellular extracellular matrix (dECM) in a drug-activated bone cell Wnt signal. The dECM bio-ink based on drug activated bone cell Wnt signals and the PCL are used for constructing the composite scaffold through 3D printing, the composite scaffold is used for repairing critical bone defects and retaining a microstructure and bioactive components of a natural bone matrix, and osteogenic differentiation, osteoclast generation, angiogenesis and neurogenesis of bone marrow stromal cells BMSCs can be remarkably promoted.

Aspects of the invention are directed to methods of stimulating or promoting neurogenesis by administering to a subject of a composition comprising a cyclodextrin and a polyethylene glycol to alleviate learning, memory and cognitive deficits present in subjects afflicted with various brain disorders or from neurodegenerative disorder associated with aging.

The invention discloses application of polypeptide in preparation of a medicine for treating brain injury, and belongs to the technical field of biological medicine. The inventor finds that the SASH1-PKM2 axis is a key node for regulating and controlling the metabolic state of astrocytes and nerve regeneration through early-stage research, so that the polypeptide for blocking the interaction of the SASH1-PKM2 is developed as a metabolic remodeling innovative medicine, and a brand new treatment strategy is provided for a patient with brain injury.

The invention discloses application of human amniotic epithelial stem cells in preparation of drugs for treating depression diseases. The human amniotic epithelial stem cells are harvested after being subjected to pancreatin digestion, centrifugation and resuspension in sequence after being cleaned by mechanically separating an amnion on the inner surface of a discarded in-vitro placenta tissue; and a human amniotic epithelial stem cell regimen for the treatment of depression; the cell is wide in source, free of ethical dispute, low in immunogenicity and free of tumorigenicity, and a novel safe and effective way is provided for depression treatment. The cell preparation can be administered through intravenous injection, intrathecal injection or nasal delivery, and the action mechanism of the cell preparation is that the cell preparation can inhibit excessive activation of glial cells and relieve depression-related neuroinflammatory response, so that the neuron microenvironment is improved. The traditional Chinese medicine composition can effectively promote hippocampal neurogenesis (DCX positive cell increase and the like), regulate the activity of 5-hydroxytryptamine neurons and glutamic acid neurons to restore the steady state of a neural network, and remarkably improve the depression-like behavior of a model mouse.

The application discloses a preparation method of a deer antler-DCB@EVsABPCs bone graft material, and specifically comprises the following steps: step 1, preparing an Antler-DCB support; step 2, preparing a 10% HAMA hydrogel and ABPCs-EVs; step 3, mixing; step 4, taking the Antler-DCB and immersing it into the HAMA hydrogel containing the ABPCs-EVs; and step 5, exposing to 405 nm ultraviolet light for 30 seconds to obtain the bone graft material. The application further discloses the deer antler-DCB@EVsABPCs bone graft material. The deer antler-DCB@EVsABPCs bone graft material and the preparation method thereof disclosed by the application have a strong ability to regulate osteogenesis, angiogenesis, neurogenesis and immune response, thereby providing a potential therapeutic intervention measure for treating serious bone defects.

In some aspects, disclosed herein are methods and compositions for treatment or prevention of cerebral palsy using fibroblasts or derivatives thereof. Disclosed herein are fibroblasts and derivatives thereof capable of inducing neurogenesis and / or reducing inflammation in a subject. In some cases, the disclosed methods comprise use of conditioned fibroblasts. Fibroblasts may be conditioned with agents capable of enhancing therapeutic efficacy, for example oxytocin and / or human chorionic gonadotrophin (hCG).

The invention relates to a polypeptide, a derivative of the polypeptide, a conjugate of the polypeptide and new application of the polypeptide. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide can reverse the weakening of cell proliferation activity of mouse hippocampal neuron cells HT-22 induced by an A beta1-40 oligomer, and reduce p-Tau protein overexpression and cell axon structure damage in the HT-22 cells caused by the A beta1-40 oligomer; the polypeptide promotes the proliferation and differentiation of the neural stem cell line C17.2 cells treated by the A beta1-40 oligomer; the polypeptide can significantly improve Alzheimer's disease related pathological changes in cerebral cortex and hippocampus of a mouse and promote neurogenesis of the hippocampus, so that related cognitive functions of learning, memory and the like of an Alzheimer's disease model mouse are recovered, and the effect of treating the Alzheimer's disease is achieved; the polypeptide can be used for preparing a low-toxicity, safe and effective Alzheimer's disease therapeutic agent, and a new way is provided for treating Alzheimer's disease.

Embodiments disclose systems and apparatus that provide neurogenesis activation by FUS stimulation including activating quiescent NSCs in the subventricular zone of the lateral ventricles and promoting the proliferation of NSCs and subsequent differentiation into newly regenerated neurons. Also disclosed is a conventional MRI guided tFUS system programmed for use with ultrasonic activation of NSCs. A wireless electronic driving configuration for transcranial use under MRI guidance is provided and a cylindrically distributed ultrasound transducer array design to provide increased steering range in at least two axes. A close integration of tFUS with MRI navigation, achieved by a novel wearable thin-film MRI coil array tightly integrated with the transducer array, enables full navigation performance of MRI in real time during FUS treatment.